# Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

> **NCT01274273** · PHASE2 · UNKNOWN · sponsor: **University of Aarhus** · enrollment: 118 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Interleukin-2
- **DRUG:** Interferon Alfa-2b
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01274273
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2014-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01274273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01274273, "Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01274273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*